Adverse effects of bevacizumab and their management in solid tumors

Supportive Cancer Therapy

Volumn 3, Issue 4, 2006, Pages 247-250

  Arriaga, Yull ^b   Becerra, Carlos R ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Bleeding; Gastrointestinal perforations; Hypertension; Proteinuria; Thrombosis; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUOROURACIL; IRINOTECAN; PLACEBO; WARFARIN;

CLINICAL TRIAL; CONFERENCE PAPER; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; PROTEINURIA; SOLID TUMOR; THROMBOSIS;

EID: 33749464563     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.023     Document Type: Conference Paper

References (15)

1. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(16 suppl):1s (Abstract #2).
2. Miller K, wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab a first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 95:(suppl1):S6(Absrract #3)
3. Sandler AB, Gray J, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-4599. J Clin Oncol 2005; 23(16 suppl):2s (Abstract #LBA4).
4. Eskens F. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004; 90:1-7.
5. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88:1979-1986.
6. Willett CG, Boucher Y, diTomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [published erratum in Nat Med 2004; 10:649]. Nat Med 2004; 10:145-147.
7. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
8. Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
10. Nakamura T, Saito T, Kusaka, et al. Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron 2002; 92:445-448.
11. Yany R, Ogasawara AK, Zioncheck TF, et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypersensitive rats. Hypertension 2002; 39:815-820.
12. Martel CL, Ebrahimi B, Horns RC, et al. Incidence of bevacizumab (BE) related toxicities: association of hypertension (HTN) and protein-uria (PTN), a BE toxicity syndrome (BETS). J Clin Oncol 2005; 23(16 suppl):744s (Abstract #8062).
13. Kanellis J, Levidiotis V, Khong T, et al. A study of VEGF and its receptors in two rat models of proteinuria. Nephron Physiol 2004; 96:P26-P36.
14. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
15. Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results from a randomized phase ill trial. J Clin Oncol 2005; 23:3697-3705.